4-(3,5-Bis-cyclopropylmethoxy-phenyl)-2-ethyl-6-methoxy-quinazolin-7-ol | 219126-30-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-(3,5-Bis-cyclopropylmethoxy-phenyl)-2-ethyl-6-methoxy-quinazolin-7-ol
• 英文别名: 4-[3,5-bis(cyclopropylmethoxy)phenyl]-2-ethyl-6-methoxyquinazolin-7-ol
• CAS: 219126-30-4
• 化学式: C₂₅H₂₈N₂O₄
• 分子量: 420.508
• InChiKey: BIMKWTXBXDRUEQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  31
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  73.7
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  羟甲基环丙烷 、 4-(3,5-Bis-cyclopropylmethoxy-phenyl)-2-ethyl-6-methoxy-quinazolin-7-ol 在 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 生成 4-(3,5-Bis-cyclopropylmethoxy-phenyl)-7-cyclopropylmethoxy-2-ethyl-6-methoxy-quinazoline
  参考文献：
  名称：

  Quinazolines: Combined type 3 and 4 phosphodiesterase inhibitors

  摘要：

  A series of quinazolines has been prepared and evaluated for its ability to inhibit cyclic AMP phosphodiesterase type 3, type 4A, 4B and 4D. The most potent inhibitors showed IC50 values in the nanomolar range far type 3 and type 4 isoforms and bind with high affinity to the [H-3]rolipram binding site. These quinazolines represent a new family of potent mixed PDE 3 / 4 inhibitors and are expected to have a therapeutic potential. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00508-3
• 作为产物：
  描述：

  2-甲氧基-5-氨基苯酚 在 palladium on activated charcoal bis-triphenylphosphine-palladium(II) chloride 、 四(三苯基膦)钯 、 氢气 、 potassium carbonate 、 N,N-二甲基苯胺 、 三乙胺 、 三氟乙酸 、 sodium iodide 、 三氯氧磷 作用下， 以 四氢呋喃 、 乙醇 、 丁酮 、 xylene 为溶剂， 反应 9.0h， 生成 4-(3,5-Bis-cyclopropylmethoxy-phenyl)-2-ethyl-6-methoxy-quinazolin-7-ol
  参考文献：
  名称：

  Quinazolines: Combined type 3 and 4 phosphodiesterase inhibitors

  摘要：

  A series of quinazolines has been prepared and evaluated for its ability to inhibit cyclic AMP phosphodiesterase type 3, type 4A, 4B and 4D. The most potent inhibitors showed IC50 values in the nanomolar range far type 3 and type 4 isoforms and bind with high affinity to the [H-3]rolipram binding site. These quinazolines represent a new family of potent mixed PDE 3 / 4 inhibitors and are expected to have a therapeutic potential. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00508-3

文献信息

• Quinazolines: Combined type 3 and 4 phosphodiesterase inhibitors
  作者：Brigitte Charpiot、Jvan Brun、Irene Donze、Reto Naef、Monique Stefani、Thomas Mueller

  DOI：10.1016/s0960-894x(98)00508-3

  日期：1998.10

  A series of quinazolines has been prepared and evaluated for its ability to inhibit cyclic AMP phosphodiesterase type 3, type 4A, 4B and 4D. The most potent inhibitors showed IC50 values in the nanomolar range far type 3 and type 4 isoforms and bind with high affinity to the [H-3]rolipram binding site. These quinazolines represent a new family of potent mixed PDE 3 / 4 inhibitors and are expected to have a therapeutic potential. (C) 1998 Elsevier Science Ltd. All rights reserved.